Monday - Friday - 8:00 - 16:30   |   Weekends - Closed

Aurum International

The Aurum Institute is a proudly South African, not-for-profit, public-benefit-organisation with a 20-year successful track record in and beyond the borders of South Africa into sub-Saharan Africa and beyond.

Aurum Institute is expanding its global footprint and has recently been involved in research extending beyond the South African borders, through the following innovative programs:
  • Aurum is the Lead Organisation implementing IMPAACT4TB (Increasing Market and Public health outcomes through scaling up Affordable Access models of short Course preventive therapy for TB) project, to prevent people most vulnerable to developing active TB, including people living with HIV and children under age five, from developing active TB disease. Aurum leads the four-year UNITAID funded grant with support from the World Health Organization, to implement the project in 12 countries in Africa, Latin America and Asia with high burdens of TB or TB/HIV.
  • WHIP3TB trial, a randomized trial evaluating the use of the 3HP regimen for PLHIV.
  • Aurum is the coordinating partner for the TB-Sequel project, a project to understand the clinical, microbiologic, and host immune factors affecting or predicting the long-term sequelae and socio-economic impact of pulmonary tuberculosis and treatment outcome, funded by the German Federal Ministry of Education and Research (BMBF) and taking place in Tanzania, The Gambia, Mozambique and South Africa.
  • PHOENix MDR-TB is being developed as a two stage study with A5300/P2003 referred to as the “PHOENix Feasibility Study.” Developing and implementing a smaller feasibility study was recommended because of the large scope of the study to ensure the Networks can successfully conduct a household contact study at sites in Africa, South America and Asia. For household contacts of someone with MDR-TB, most high burden countries are implementing the WHO policy of “watch and wait.” This means that household contacts continue to remain at risk of developing the disease, which may be especially dangerous for small children.
  • Through the Evidence for HIV Prevention Southern and Eastern Africa (EHPSA) fund, we are leading a project which is evaluating HIV treatment in prisons in Zambia and South Africa, and also a systematic review and evaluation of M&E systems in prisons in Mozambique, Zambia, Mauritius, Tanzania and Malawi.
Please contact Karin Turner, Director of IMPAACT4TB for any additional information. This email address is being protected from spambots. You need JavaScript enabled to view it.